Navigation Links
Studies show LAM patients participate in clinical trials to help others, not themselves

CINCINNATITwo recent studies by researchers at the University of Cincinnati (UC) bring to light interesting findings about the diagnosis of the rare lung disease Lymphangioleiomyomatosis ( LAM) and the reasons LAM patients participate in research studies.

Brent Kinder, MD, Frank McCormack, MD, and Jared Hagaman, MD, working with colleagues in the division of pulmonary, critical care and sleep medicine at UC, found that patients with LAM were more likely to participate in clinical trials because of a shared cause and a feeling of altruism, as opposed to personal benefit.

In addition, this team found that CT scans given to young women who come to the emergency room for the first time with a collapsed lung are cost-effective and beneficial.

These findings will be presented at the American Thoracic Society International Conference in San Diego May 15-20.

LAM is a rare but serious lung disease that occurs when an unusual type of cell begins to grow out of control and spread to restricted areas in the body, including the lungs, kidneys, lymph nodes and vessels.

In the first study, 918 LAM patients in North America were surveyed to determine who participated in clinical trials and why. Of the 918 surveyed, 263 patients responded.

"Age, disease duration, use of oxygen therapy and disease presentation without chest pain were associated with trial participation, but the desire to help others with similar health problems was at the top of list," says Kinder, also director of the Interstitial Lung Disease Center at UC.

Results showed that 16 percent of LAM patient respondents participated in a clinical trial, but 85 percent of those people participated to help future patients.

In addition, results showed that the usual barriers to trial participation, like time constraints, risk of taking a placebo and geographic location, were found to be less important for LAM patients.

In a separate study, Kinder and colleagues found that it is cost-effective to do CT scan screening of non-smoking women, ages 25-54, who come to the emergency room for the first time with a collapsed lungan early predictor of LAMin order to diagnose and treat those with the illness.

"A major contributor to morbidity in patients with LAM is spontaneous pneumothorax, or a collapsed lung," Kinder says. "Seventy percent of patients with LAM will have at least one and most will have one or more recurrences. Due to lack of awareness and non-specific nature of most symptoms, the diagnosis of LAM is often delayed for several years into the disease.

"A CT scan for women of child-bearing age who experience a collapsed lung could help with a faster diagnosis, thereby improving outcomes."

Kinder says the results of these studies can help identify the disease in its early stages and find more effective treatments for patients with LAM.

"The more quickly we can detect the illness, the better chance a patient has of prolonging her life in addition to introducing the patient to novel therapies through clinical trials, which could help others as well," he says.


Contact: Katie Pence
University of Cincinnati Academic Health Center

Related medicine news :

1. Traumatic brain injury haunts children for years with variety of functional problems: Two studies
2. Review finds conflicts of interest in many cancer studies
3. Studies Report Use of USGI Medicals Incisionless Operating Platform(TM) (IOP) in Numerous Incisionless Surgical Procedures
4. Physicians Conduct Research Studies in Minutes, Not Months, at Montefiore Medical Center
5. Kessler Foundation Research Center Presented Two Studies on Post-stroke Spatial Neglect at American Academy of Neurology
6. Studies uncover high and often overlooked costs associated with epilepsy
7. Are we cherry picking participants for studies of antidepressants?
8. Wound Management Technologies, Inc. Announces the Presentation of Evidence Based Clinical Studies at the Symposium on Advanced Wound Care Conference in Dallas
9. Pharos Innovations and Clients to Showcase Three Client Case Studies at Upcoming ATA Conference
10. Gene Studies Reveal Cancers Secrets
11. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
(Date:6/23/2016)... 2016 The Biotechnology industry might ... present great opportunities to investors. assesses the recent ... (NYSE: XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... receive your complimentary trade alerts at: ...
(Date:6/23/2016)... , June 23, 2016 Leading BioSciences ... address medical conditions resulting from a breakdown of ... appointed Greg Doyle as chief executive ... BioSciences, executive management team and board of directors, ... financial officer. He will provide continued leadership and ...
Breaking Medicine Technology: